<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614728</url>
  </required_header>
  <id_info>
    <org_study_id>208809</org_study_id>
    <nct_id>NCT03614728</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase I/II Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents in Participants With Myelodysplastic Syndrome and Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability, and clinical activity of GSK3326595 in&#xD;
      participants with relapsed and refractory MDS, chronic myelomonocytic leukemia (CMML), and&#xD;
      AML. The study will be conducted in 2 parts: Part 1 will determine the clinical benefit rate&#xD;
      (CBR) of GSK3326595 in monotherapy and Part 2 will be expanded to study GSK3326595 in&#xD;
      combination with 5-Azacitidine which will be composed of a dose escalation phase followed by&#xD;
      dose expansion cohort of GSK3326595.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2018</start_date>
  <completion_date type="Anticipated">April 23, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is an open-label, multicenter, multi-part study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Percentage of participants with clinical benefit rate (CBR)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>CBR is defined as the percentage of participants achieving a complete remission (CR), complete marrow remission (mCR), partial remission (PR), stable disease (SD) lasting at least 8 weeks, or hematologic improvement (HI), per International Working Group (IWG) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Dose escalation: Number of participants with adverse events and serious adverse events (AEs and SAEs)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>All AEs and SAEs will be collected.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Dose escalation: Number of participants achieving dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets the Non-hematologic toxicity, hematologic toxicity and other toxicity criteria unless it can be clearly established that the event is unrelated to treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Dose escalation: Number of participants with dose interruptions, dose reductions and treatment discontinuation due to adverse events.</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Participants with dose interruptions, dose reductions and treatment discontinuation due to adverse events will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2 Dose expansion: Number of participants achieving CR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Complete remission (CR) rate is defined as the percentage of participants achieving a CR per International Working Group (IWG) criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2 Dose expansion: Number of participants with AEs and SAEs</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>All AEs and SAEs will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of participants achieving DLTs</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets the Non-hematologic toxicity, hematologic toxicity and other toxicity criteria unless it can be clearly established that the event is unrelated to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, Part 2 Dose escalation and dose expansion: Percentage of participants achieving overall response rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Overall response rate is defined as the percentage of participants achieving a CR, mCR, or PR, per IWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Progression-free survival (PFS)</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>PFS is defined as time from first dose to disease progression, as defined by IWG criteria, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Overall survival</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Overall survival is defined time from first dose to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Observed Plasma Concentration (Cmax) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine Cmax of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time of maximum concentration observed (Tmax) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine Tmax of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent terminal phase half-life (t1/2) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine t1/2 of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under Concentration-time Curve from time zero (pre-dose) to last time of quantifiable concentration within participant across all treatments (AUC[0-t]) of GSK3326595</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-t) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC from 0 hours to the time of next dosing (AUC[0-tau]) of GSK3326595</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-tau) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC(0-inf) from time zero to infinity (AUC[0-inf]) of GSK3326595</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-inf) of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Oral clearance (CL/F) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine CL/F of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time invariance (TI) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine TI of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Accumulation ratio (AR) of GSK3326595 in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AR of GSK3326595.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation: Number of participants achieving CR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>CR rate is defined as the percentage of participants achieving a CR per IWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: Cmax of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine Cmax of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: Tmax of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine Tmax of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: t1/2 of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine t1/2 of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: AUC(0-t) of GSK3326595 and 5-azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-t) of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: AUC(0-inf) of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-inf) of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: AUC(0-tau) of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AUC(0-tau) of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: CL/F of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine CL/F of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: TI of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine TI of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose escalation and dose expansion: AR of GSK3326595 and 5-Azacitidine in plasma following single- (Day 1) and repeat-dose administration</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Blood samples will be collected to determine AR of GSK3326595 and 5-Azacitidine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 Dose expansion: Number of participants with dose interruptions, dose reductions and treatment discontinuation due to adverse events.</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Participants with dose interruptions, dose reductions and treatment discontinuation due to adverse events will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">113</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Part 1: Participants receiving GSK3326595</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3326595</intervention_name>
    <description>GSK3326595 will be administered.</description>
    <arm_group_label>Part 1: Participants receiving GSK3326595</arm_group_label>
    <arm_group_label>Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
    <arm_group_label>Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Azacitidine</intervention_name>
    <description>5-Azacitidine will be administered.</description>
    <arm_group_label>Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
    <arm_group_label>Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females greater than or equal to (&gt;=)18 years of age (at the time consent is&#xD;
             obtained).&#xD;
&#xD;
          -  Diagnosis of MDS, CMML or AML&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 or 2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  A woman of childbearing potential (WOCBP) must have a negative highly sensitive serum&#xD;
             pregnancy test within 7 days before the first dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or known, central nervous system (CNS) involvement&#xD;
&#xD;
          -  Prior solid organ transplantation&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to GSK3326595 or 5-Azacitidine or&#xD;
             its excipient&#xD;
&#xD;
          -  Prior therapy with any Protein arginine methyl transferase 5 (PRMT5) inhibitor&#xD;
&#xD;
          -  History of a second malignancy, excluding non-melanoma skin cell cancer, within the&#xD;
             last three years&#xD;
&#xD;
          -  Active severe or uncontrolled infection&#xD;
&#xD;
          -  History of optic nerve neuropathy or neuritis.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof, or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or Medical&#xD;
             Monitor, contraindicates their participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kimo Bachiashvili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Justin Watts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Brunner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gautam Borthakur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sameem Abedin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Minden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>GSK3326595</keyword>
  <keyword>5-Azacitidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>GSK-3326595</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

